BioSenic Advances Autoimmune Pipeline and Explores Strategic M&A Opportunities
• BioSenic is actively pursuing strategic mergers and acquisitions to expand its asset portfolio, focusing on opportunities within the biopharmaceutical sector.
• Positive Phase II clinical data for arsenic trioxide (ATO) in chronic Graft-versus-Host Disease (cGvHD) supports plans for a Phase III trial, pending FDA review.
• Clinical trials for Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc) are in the planning stages, contingent on securing partnerships or out-licensing agreements.
© Copyright 2025. All Rights Reserved by MedPath